Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017136
Chunk: 15

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 15
---
   9,600,000 |     | *            |     |          -- |     | --            |
| S.H.N Financial Investments Ltd (14)             |     |   9,600,000 |     | *            |     |   9,600,000 |     | *            |     |          -- |     | --            |
| Walleye Opportunities Master Fund Ltd (15)       |     |   9,100,000 |     | *            |     |   9,100,000 |     | *            |     |          -- |     | --            |

________________

| * | Represents beneficial ownership of less than one percent. |

| ** | Subject to beneficial ownership blocker. See notes below. |

| *** | Based                                          
 upon 61,952,308,922 Ordinary Shares issued and 
 outstanding as of November 1, 2025.            |

| (1) | The selling shareholder holds Series                                                            
 D Warrants which entitle the selling shareholder to purchase an aggregate of 4,800,000 Ordinary 
 Shares, which we are registering hereby. The warrants are subject to a beneficial ownership     
 limitation of 9.99%, which does not permit the selling shareholder to exercise that portion     
 of the warrants that would result in the selling shareholder and its affiliates owning, after   
 exercise, a number of our Ordinary Shares in excess of the beneficial ownership limitation.     
 The amounts and percentages in the table do not give effect to the 9.99% beneficial ownership   
 limitation, if applicable. The principal business address of Seven Knots LLC is 7 Rose Avenue,  
 Great Neck, NY 11021.                                                                           |

| (2) | The selling shareholder holds (i)                                                                
 warrants issued by us in a prior transaction which entitle the selling shareholder to purchase   
 an aggregate of 100,000 Ordinary Shares (in the form of Depositary Shares) and (ii) Series       
 D Warrants which entitle the selling shareholder to purchase an aggregate of 9,600,000 Ordinary  
 Shares, which we are registering hereby. The warrants are subject to a beneficial ownership      
 limitation of 9.99%, which does not permit the selling shareholder to exercise that portion      
 of the warrants that would result in the selling shareholder and its affiliates owning, after    
 exercise, a number of our Ordinary Shares in excess of the beneficial ownership limitation.      
 The securities are directly held by the Armistice Capital Master Fund, LP, and may be